癌症相關厭食症市場－全球及區域/國家分析與預測（2025-2035）

癌症厭食症是指癌症患者出現食慾顯著下降和食物攝取量減少的疾病。

這是一種複雜的、多因素引起的症狀，在晚期癌症患者中尤其常見。它並非單純的食慾不振，而是一種涉及複雜生理和心理因素的多因素症候群，在晚期癌症的後期階段尤其常見。癌症相關性厭食症可導致營養不良和惡病質，顯著降低患者的生活品質。

癌症厭食症市場是腫瘤治療領域一個新興且充滿活力的細分市場，旨在解決癌症患者通用的厭食症和惡病質等複雜症狀。該市場的成長得益於癌症發病率的上升、藥物研發的進步以及對有效治療方法厭食症及相關症狀的需求不斷成長。全球癌症患者數量的增加直接推動了對癌症厭食症治療需求的成長。

近年來，食慾促效劑和抗惡病質藥物的研發推動了市場成長。此外，醫護人員和患者對惡病質和厭食症的認知不斷提高，促進了早期診斷和治療。人們日益認知到惡病質是一種多因素疾病，會顯著影響存活率和生活品質，這加速了該領域的研究和發展。此外，美國國家癌症研究所 (NCI) 和美國癌症協會 (ACS) 等機構的宣傳宣傳活動和研究津貼也有助於傳播相關知識，提高診斷率，從而進一步推動了市場成長。

然而，現有藥物療效有限，且可能伴隨體重增加、水腫和認知障礙等副作用，限制了部分患者的使用。此外，新型生物製藥和聯合治療等創新治療方法高成本且難以取得，尤其是在中低收入國家。而且，醫療保險體系往往無法充分涵蓋這些治療，限制了患者獲得有效治療的機會。

此外，由於缺乏國際公認的癌症相關厭食症治療指南，在臨床環境中實施標準化治療存在障礙，導致患者治療結果不一致。

市場的主要成長機會包括新型生物製劑、荷爾蒙療法和食慾促效劑的研發。例如，一些具有全新作用機制的治療方法，如Ghrelin釋放肽模擬物和肌肉生長抑制素抑制劑，正被研究作為治療惡病質和厭食症的新方法。此外，將食慾促效劑與現有癌症療法（如免疫查核點抑制劑和化療）合併使用，可望提高療效。此類聯合治療可望同時改善多種症狀，例如食慾不振、疲勞和肌肉萎縮，進而改善患者的整體治療效果。

精準醫療在癌症厭食症治療領域正廣泛應用，治療方法根據每位患者的基因和分子特徵進行最佳化，從而最大限度地提高療效並減少副作用。營養支持在癌症厭食症治療中的重要性也日益受到重視。管飼和全腸外營養擴大作為藥物治療的輔助手段，幫助患者維持營養狀況。

本報告檢視了全球癌症厭食症市場，並總結了關鍵趨勢、市場影響因素分析、法律制度、市場規模趨勢和預測、按各個細分市場和主要國家/地區進行的詳細分析、競爭格局以及主要企業的概況。

目錄

執行摘要

第1章 全球癌症厭食症市場：產業展望

• 市場概覽
• 按地區分類的癌症相關厭食症的流行病學分析
• 監管狀態
• 主要趨勢
• 臨床試驗分析
• 市場動態
  • 影響分析
  • 市場促進因素
  • 市場約束
  • 市場機遇

2. 全球癌症厭食症市場（按地區分類）

• 北美洲
• 歐洲
• 亞太地區
  • 市場動態
  • 市場規模及預測

第3章 全球癌症厭食症市場：競爭格局與公司概況

• 競爭格局
  • 關鍵策略和發展（按公司分類）
• 公司簡介
  • NGM Biopharmaceuticals
  • Artelo Biosciences
  • 其他

第4章調查方法

Global Cancer Anorexia Market, Analysis and Forecast: 2025-2035

Cancer anorexia refers to a condition characterized by a significant loss of appetite and a reduced intake of food in cancer patients. It is a complex and multifactorial symptom commonly seen in those with advanced cancer, particularly in the later stages of the disease. Cancer anorexia is not simply a lack of desire to eat, but often a profound physical and psychological condition that can contribute to malnutrition, cachexia, and a decline in overall quality of life.

The cancer anorexia market is an emerging and dynamic segment of oncology treatment, addressing the complex symptoms of anorexia and cachexia commonly observed in cancer patients. This market is influenced by several factors, including increasing cancer prevalence, advancements in drug development, and the rising need for effective treatments to manage anorexia and associated symptoms. The growing global burden of cancer significantly contributes to the rising demand for treatments addressing cancer anorexia.

Moreover, the development of new appetite-stimulating drugs and anti-cachexia medications plays a significant role in driving the market. Furthermore, increased awareness about cancer cachexia and anorexia among healthcare professionals and patients is leading to earlier diagnosis and treatment initiation. Greater recognition of cachexia as a multifactorial condition with a substantial impact on survival and quality of life has accelerated research and drug development in this area. Also, awareness campaigns and research grants from organizations like the National Cancer Institute (NCI) and American Cancer Society (ACS) are boosting knowledge and diagnosis, further fueling the market growth.

Despite advancements, current drugs often provide only limited efficacy and can be associated with side effects such as weight gain, fluid retention, and cognitive issues. This limits their widespread use in some patients, and a need for more effective therapies persists. Additionally, the cost of innovative treatments for cancer anorexia, such as newer biologic therapies and combination approaches, remains high, limiting their accessibility, especially in low- and middle-income countries. Moreover, healthcare reimbursement policies may not fully cover the expenses of these therapies, making it challenging for some patients to access effective care.

The lack of universally accepted clinical guidelines for the management of cancer anorexia makes it difficult for healthcare providers to adopt standardized treatment protocols, potentially leading to inconsistent patient outcomes.

The development of new biologics, hormonal therapies, and novel appetite stimulants represents a major opportunity in the market. For example, ghrelin mimetics and myostatin inhibitors are being explored as new treatment avenues for cachexia and anorexia. Furthermore, combining appetite stimulants with other cancer treatments, such as immune checkpoint inhibitors or chemotherapy, may offer enhanced efficacy. Combination therapies can address multiple aspects of anorexia, including appetite loss, fatigue, and muscle wasting, improving overall patient outcomes.

Precision medicine is a growing trend in the cancer anorexia market, where treatments are tailored to individual patient profiles based on genetic and molecular factors. This approach aims to optimize therapy effectiveness and minimize side effects. Moreover, there is a growing recognition of the role of nutritional support in managing cancer anorexia. The use of enteral feeding tubes and parenteral nutrition is becoming more common as an adjunct to pharmacological therapies, helping to meet the nutritional needs of patients.

The cancer anorexia market is highly competitive, with a mix of established pharmaceutical companies and emerging biotech firms innovating in the space. Many companies are focusing on developing combination therapies and biologic agents that address both the symptoms of cancer anorexia and the underlying conditions, such as cachexia. Innovative treatments, such as ghrelin mimetics and muscle-wasting agents, are being explored to target hormonal pathways and stimulate appetite in cancer patients, offering new therapeutic options. Additionally, there is growing interest in combining immune therapies with appetite stimulants to improve treatment efficacy. As research in biologic therapies and precision medicine continues, the market is evolving with more targeted and effective solutions aimed at enhancing patient outcomes and addressing the multifaceted nature of cancer anorexia and cachexia.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Cancer Anorexia Market: Industry Outlook

• 1.1 Market Overview
• 1.2 Epidemiological Analysis of Cancer Anorexia, By Region
• 1.3 Regulatory Landscape
• 1.4 Key Trends
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraint
  • 1.6.4 Market Opportunities

2. Global Cancer Anorexia Market, by Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Sizing and Forecast
    • 2.1.2.1 North America Cancer Anorexia Market, by Country
      • 2.1.2.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Sizing and Forecast
    • 2.2.2.1 Europe Cancer Anorexia Market, by Country
      • 2.2.2.1.1 Germany
      • 2.2.2.1.2 U.K.
      • 2.2.2.1.3 France
      • 2.2.2.1.4 Italy
      • 2.2.2.1.5 Spain
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Sizing and Forecast
    • 2.3.2.1 Asia-Pacific Cancer Anorexia Market, by Country
      • 2.3.2.1.1 Japan

3. Global Cancer Anorexia Market -Competitive Landscape and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments, by Company
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations, and Business Expansions
• 3.2 Company Profiles
  • 3.2.1 NGM Biopharmaceuticals
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Top Competitors
    • 3.2.1.4 Target Customers/End-Users
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 Artelo Biosciences
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Top Competitors
    • 3.2.2.4 Target Customers/End-Users
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 Others

4. Research Methodology

List of Figures

• Figure: Cancer Anorexia Market (by Scenario), $Million, 2024, 2030, and 2035
• Figure: Global Cancer Anorexia Market, 2024 and 2035
• Figure: Global Cancer Anorexia Market Key Trends, Impact Analysis, 2023-2035
• Figure: North America Cancer Anorexia Market, $Million, 2023-2035
• Figure: Europe Cancer Anorexia Market, $Million, 2023-2035
• Figure: Asia-Pacific Cancer Anorexia Market, $Million, 2023-2035

List of Tables

• Table: Market Snapshot
• Table: Global Cancer Anorexia Market, Market Dynamics, Impact Analysis
• Table: Global Cancer Anorexia Market (by Region), $Million, 2023-2035